In policy, continued alignment of allocation rules with tumour biology is essential, incorporating AFP- and DCP-anchored thresholds, response-weighted exceptions, and harmonised LI-RADS imaging language across jurisdictions. The gene discussed is AFP; the disease is neoplasm.